HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP.

Abstract
The first phase I study of cystic fibrosis gene therapy using cationic liposomes to deliver the cystic fibrosis conductance regulator gene to the nose reported partial and transient correction of the nasal transepithelial ion transport defect, While encouraging, further improvements will be required if this form of treatment is to be of therapeutic value. We tested a new formulation, pCMV-CFTR-DOTAP. The complex is stable for 10 days and effective at correcting the electrophysiological deficit in the trachea of CF mutant mice at 8 or 9 days after intratracheal instillation. Reliable protocols for consistent detection of as few as 10 molecules of CFTR mRNA and DNA in nasal brushing samples are described, Both vector and DNA have been produced to Good Manufacturing Practice standard, Nasal potential difference measurements developed at the National Heart and Lung Institute to assess the CFTR ion channel activity in CF patients replicated well at the Scottish Adult Cystic Fibrosis Service. The SPO fluorescence assay for halide ion conductance in nasal brushings has also been tested. These establish baseline conditions in the Scottish CF cohort from which evidence for correction can be judged under clinical trial conditions. These studies formed the basis for regulatory approval of a randomised, placebo controlled double-blind phase I research study.
AuthorsG McLachlan, L P Ho, H Davidson-Smith, J Samways, H Davidson, B J Stevenson, A D Carothers, E W Alton, P G Middleton, S N Smith, G Kallmeyer, U Michaelis, S Seeber, K Naujoks, A P Greening, J A Innes, J R Dorin, D J Porteous
JournalGene therapy (Gene Ther) Vol. 3 Issue 12 Pg. 1113-23 (Dec 1996) ISSN: 0969-7128 [Print] England
PMID8986438 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Aerosols
  • CFTR protein, human
  • Fatty Acids, Monounsaturated
  • Liposomes
  • Pharmaceutical Vehicles
  • Quaternary Ammonium Compounds
  • Quinolinium Compounds
  • RNA, Messenger
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • 6-methoxy-N-(3-sulfopropyl)quinolinium
  • 1,2-dioleoyloxy-3-(trimethylammonium)propane
Topics
  • Aerosols
  • Animals
  • COS Cells
  • Clinical Trials, Phase I as Topic
  • Cystic Fibrosis (genetics, therapy)
  • Cystic Fibrosis Transmembrane Conductance Regulator (genetics)
  • Cytomegalovirus (genetics)
  • Fatty Acids, Monounsaturated
  • Genetic Therapy
  • Genetic Vectors
  • Humans
  • Liposomes
  • Membrane Potentials
  • Mice
  • Nasal Mucosa (metabolism, physiology)
  • Pharmaceutical Vehicles
  • Quaternary Ammonium Compounds
  • Quinolinium Compounds
  • RNA, Messenger (analysis, genetics)
  • Transfection

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: